
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOV3lQcmlldnhPX1N4NWpJZ21rT0lXVGdNRjZzUVVFX3pGaS1fem4xRG1CQ1JYaHFSNzhKTW1hUEZyYjd3VVRzcWlzSW4zUy1EUllLVzRYOXltZElUNDhadWVKekJZWXFnQVZ5VTZhN2JwbU5nNG1aRExYR3NjSG0wYkJSZVpnRnRKWHpFdVcyZF9UUG5DakFVbWlnZWJZeUZLdG9hSmtVQnVhQ3I0dUhZUWtEcmRkNi01QnpKalBR?oc=5" target="_blank">LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026</a>&nbsp;&nbsp;<font color="#6f6f6f">Biogen</font>

